News & Videos - CARDIOME PHARMA

Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV PR Newswire VANCOUVER, May 17, 2018 Nasdaq: CORV TSX: CORV VANCOUVER , May 17, 2018 /PRNewswire/ - Correvio Pharma Corp. (Nasdaq:CORV / TSX:CORV), formerly Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Nasdaq and the Toronto Stock Exchange (TSX) have approved changes to the Company's stock ticker symbols....

Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals PR Newswire VANCOUVER, May 15, 2018 NASDAQ: CRME TSX: COM Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital VANCOUVER , May 15, 2018 /PRNewswire/ - Correvio Pharma Corp. ("Correvio"), formerly Cardiome Pharma Corp. ("Cardiome") (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today...

Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call PR Newswire VANCOUVER, May 10, 2018 Shareholders Approve Cipher Acquisition of Canadian Business Portfolio of Cardiome Company to Host First Quarter 2018 Financial Results Conference Call on Tuesday, May 15, 2018 at 4:30 p.m. ET NASDAQ: CRME TSX: COM VANCOUVER , May 10, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a...

Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire VANCOUVER, April 26, 2018 NASDAQ:CRME, TSX:COM VANCOUVER , April 26, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mr. David Dean , Chief Business Development Officer of Cardiome, will present at the Bloom Burton & Co. Healthcare Investor Conference. The presentation...

Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess® PR Newswire VANCOUVER, April 17, 2018 NASDAQ: CRME TSX: COM VANCOUVER , April 17, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess ® (vernakalant hydrochloride, IV), the Company's...

Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018 PR Newswire VANCOUVER, April 12, 2018 NASDAQ: CRME TSX: COM Company Will Also Host Xydalba Expert Educational Session Featuring Key Opinion Leaders in the Field of Hospital Anti-Infectives VANCOUVER , April 12, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced 15 data presentations taking...

Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds PR Newswire VANCOUVER, April 6, 2018 NASDAQ: CRME TSX: COM VANCOUVER , April 6, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome" or the "Company") today announced that it has entered into a first amending agreement to its amended and restated term loan agreement with CRG Servicing LLC ("CRG") managed funds dated May 11, 2017 (the "Amending Agreement") to provide for certain adjustments to...

Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission PR Newswire VANCOUVER, April 2, 2018 NASDAQ: CRME TSX: COM VANCOUVER , April 2, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted progress by its partner SteadyMed Therapeutics (NASDAQ:STDY) towards the resubmission of a New Drug Application (NDA) for Trevyent ® for the treatment of...

Cardiome Announces Recent Insider Purchases PR Newswire VANCOUVER, March 28, 2018 NASDAQ:CRME TSX:COM VANCOUVER , March 28, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announces that Dr. William Hunter , President and CEO and Justin Renz , Chief Financial Officer, purchased an aggregate total of 210,000 common shares of Cardiome on both the TSX and the NASDAQ on March 26 , 2018. Details of the transactions can be found on the System for Electronic Disclosure by Insiders...

Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review PR Newswire VANCOUVER, March 22, 2018 Approval Decision Expected in Third Quarter 2018 NASDAQ:CRME TSX:COM VANCOUVER , March 22, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, announced today that Health Canada has accepted its New Drug Submission (NDS) for review of...

...

Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome PR Newswire MISSISSAUGA, ON, and VANCOUVER, March 20, 2018 Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of $25.5 Million CAD MISSISSAUGA, ON , and VANCOUVER , March 20, 2018 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: CPH) and...

Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire VANCOUVER, March 13, 2018 Management to Host Conference Call and Webcast Today, March 13, 2018 at 4:30 p.m. Eastern ( 1:30 p.m. Pacific) NASDAQ: CRME TSX: COM VANCOUVER , March 13, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today reported financial results for its fourth...

Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13 PR Newswire VANCOUVER, March 6, 2018 NASDAQ:CRME TSX:COM VANCOUVER , March 6, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2017 on Tuesday, March 13, 2018 ....

Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference PR Newswire VANCOUVER, Feb. 8, 2018 NASDAQ:CRME TSX:COM VANCOUVER , Feb. 8, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Dr. Bill Hunter , President and CEO of Cardiome, will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare...

Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen PR Newswire VANCOUVER, Jan. 23, 2018 Addition of High-Risk STEMI Patients Significantly Expands the Number of Patients in Which Aggrastat Can Be Used NASDAQ:CRME TSX:COM VANCOUVER , Jan. 23, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today...

Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit PR Newswire VANCOUVER, Jan. 10, 2018 NASDAQ:CRME TSX:COM VANCOUVER , Jan. 10, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Mr. Justin Renz , Chief Financial Officer of Cardiome, will participate in a panel discussion at the Cantor Fitzgerald Antibiotics Summit. The panel,...

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia PR Newswire VANCOUVER, Dec. 12, 2017 NASDAQ:CRME TSX:COM VANCOUVER , Dec. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance...

Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission PR Newswire VANCOUVER, Dec. 11, 2017 NDA Expected to be Filed and Accepted by the End of 2018 NASDAQ:CRME TSX:COM VANCOUVER , Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that its partner SteadyMed Therapeutics (NASDAQ:STDY) has reached agreement with...

Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference PR Newswire VANCOUVER, Dec. 11, 2017 NASDAQ:CRME TSX:COM Plenary Symposium Features Three Experts Discussing Clinical Use VANCOUVER , Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017...